Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $133 | $118 | $146 | $191 |
| - Cash | $32 | $49 | $19 | $33 |
| + Debt | $6 | $13 | $10 | $15 |
| Enterprise Value | $108 | $83 | $137 | $173 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$8 | -$4 | -$9 |
| % Margin | – | – | – | – |
| Net Income | -$8 | -$8 | -$4 | -$6 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.23 | -0.28 | -0.155 | -0.25 |
| % Growth | 17.9% | -80.6% | 38% | – |
| Operating Cash Flow | -$11 | -$8 | -$1 | -$8 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$11 | -$8 | -$1 | -$8 |